Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

A Forbes; A Al-Damluji; S Ashworth; M Bramble; K Herbert; J Ho; J-Y Kang; R Przemioslo; A Shetty

doi:10.1111/j.1365-2036.2005.02442.x

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

A Forbes, A Al-Damluji, S Ashworth, M Bramble, K Herbert, J Ho, J-Y Kang, R Przemioslo, A Shetty

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

Abstract

5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR.

Original language	English
Pages (from-to)	1099-1104
Number of pages	6
Journal	Alimentary Pharmacology and Therapeutics
Volume	21
Issue number	9
DOIs	https://doi.org/10.1111/j.1365-2036.2005.02442.x
Publication status	Published - 1 May 2005

Keywords

Anti-Inflammatory Agents, Non-Steroidal
Colitis, Ulcerative
Female
Humans
Male
Mesalamine
Middle Aged
Tablets, Enteric-Coated
Treatment Outcome

Access to Document

10.1111/j.1365-2036.2005.02442.x

Cite this

Forbes, A., Al-Damluji, A., Ashworth, S., Bramble, M., Herbert, K., Ho, J., Kang, J-Y., Przemioslo, R., & Shetty, A. (2005). Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 21(9), 1099-1104. https://doi.org/10.1111/j.1365-2036.2005.02442.x

@article{41ce807743b14999872c078f741c9141,

title = "Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis",

abstract = "5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR.",

keywords = "Anti-Inflammatory Agents, Non-Steroidal, Colitis, Ulcerative, Female, Humans, Male, Mesalamine, Middle Aged, Tablets, Enteric-Coated, Treatment Outcome",

author = "A Forbes and A Al-Damluji and S Ashworth and M Bramble and K Herbert and J Ho and J-Y Kang and R Przemioslo and A Shetty",

year = "2005",

month = may,

day = "1",

doi = "10.1111/j.1365-2036.2005.02442.x",

language = "English",

volume = "21",

pages = "1099--1104",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "9",

}

Forbes, A, Al-Damluji, A, Ashworth, S, Bramble, M, Herbert, K, Ho, J, Kang, J-Y, Przemioslo, R & Shetty, A 2005, 'Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis', Alimentary Pharmacology and Therapeutics, vol. 21, no. 9, pp. 1099-1104. https://doi.org/10.1111/j.1365-2036.2005.02442.x

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. / Forbes, A; Al-Damluji, A; Ashworth, S; Bramble, M; Herbert, K; Ho, J; Kang, J-Y; Przemioslo, R; Shetty, A.

In: Alimentary Pharmacology and Therapeutics, Vol. 21, No. 9, 01.05.2005, p. 1099-1104.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

AU - Forbes, A

AU - Al-Damluji, A

AU - Ashworth, S

AU - Bramble, M

AU - Herbert, K

AU - Ho, J

AU - Kang, J-Y

AU - Przemioslo, R

AU - Shetty, A

PY - 2005/5/1

Y1 - 2005/5/1

N2 - 5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR.

AB - 5-Aminosalicylates remain important in the treatment of ulcerative colitis, but it is uncertain if the various preparations currently available are equivalent given the different delivery systems that exist. Generic prescription of mesalazine (mesalamine) is therefore inappropriate. Ipocol has recently become available as an alternative to Asacol-MR.

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Colitis, Ulcerative

KW - Female

KW - Humans

KW - Male

KW - Mesalamine

KW - Middle Aged

KW - Tablets, Enteric-Coated

KW - Treatment Outcome

U2 - 10.1111/j.1365-2036.2005.02442.x

DO - 10.1111/j.1365-2036.2005.02442.x

M3 - Article

C2 - 15854171

VL - 21

SP - 1099

EP - 1104

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -